The once-weekly injection therapy marstacimab is being considered for approval in both the U.S. and Europe for people with hemophilia A and hemophilia B who don’t have inhibitors. The U.S. Food and Drug Administration (FDA) is expected to decide on it in late 2024, while a decision from the European…
Eloctate (efmoroctocog alfa) is an extended half-life therapy that's approved to prevent and treat bleeds, including those occurring during surgery, in adults and children with hemophilia A.
Hemophilia C is a rare bleeding disorder that affects the blood’s ability to clot.
Hemophilia B is a rare genetic bleeding disorder that impairs the blood’s ability to clot properly.
Hemophilia A is a rare genetic disorder that affects the blood’s ability to clot properly. It is the most common form of hemophilia, responsible for 80% of all cases.
Last updated Nov. 21, 2023, by Margarida Maia, PhD ✅ Fact-checked by Joana Carvalho, PhD What is Obizur for hemophilia? Obizur (susoctocog alfa) is a recombinant, or man-made, antihemophilic factor therapy approved for the on-demand treatment of bleeding episodes in adults with acquired…
Rebinyn (nonacog beta pegol, or N9-GP) is an extended half-life product approved for treating and preventing bleeds, including those occurring during surgery, in adults and children with hemophilia B.
Read about Esperoct, an extended half-life infusion treatment approved to prevent or stop bleeding in children and adults with hemophilia A.
Hemophilia is a rare disorder in which a person’s blood is not able to clot properly, resulting in unusually easy and prolonged bleeding.
Venture philanthropy fund Pathway to Cures (P2C)) has invested $500,000 in Five Liters, which is developing noninvasive, nonpharmacological neuromodulation therapies for treating inheritable blood and bleeding disorders, such as hemophilia and von Willebrand disease (VWD). “Investing in Five Liters’ early-stage research is a critical step in addressing unmet…
Get regular updates to your inbox.
